Physician profile
Donald Andersen
NPI 1003846817
$7,383.05
in general payments reported to CMS, 2019-2025
51 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $478 · 2021: $308 · 2022: $549 · 2023: $1,489 · 2024: $1,718 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,619 · Education: $75.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,618.65 |
| Education | $75.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $784.15 | 2019-2025 | Myrbetriq, Xtandi, Veozah |
| Dendreon Pharmaceuticals LLC | $728.28 | 2019-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $682.05 | 2019-2025 | |
| Pfizer INC. | $521.79 | 2019-2025 | |
| Janssen Biotech, INC. | $423.23 | 2019-2025 | Erleada, Akeega |
| Procept Biorobotics Corporation | $420.47 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Sumitomo Pharma America, INC. | $349.27 | 2023-2025 | Gemtesa, Orgovyx |
| Myriad Genetic Laboratories, INC. | $299.93 | 2020-2025 | Prolaris |
| Ferring Pharmaceuticals INC. | $276.44 | 2019-2024 | Adstiladrin |
| Antares Pharma, INC. | $247.84 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Tolmar, INC. | $234.84 | 2023-2025 | Jatenzo, Eligard |
| Merck Sharp & Dohme LLC | $208.96 | 2019-2025 | Keytruda, Lynparza |
| Boston Scientific Corporation | $204.30 | 2019-2025 | Lithovue, Rezum Generator, Spaceoar Vue System - 10ml |
| Novartis Pharmaceuticals Corporation | $192.41 | 2023-2025 | |
| Abbvie INC. | $186.77 | 2022-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Andersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.